GSK buys respiratory drug maker Aiolos in $1.4bn deal
GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).
FTSE 100
8,260.10
15:45 22/11/24
n/a
n/a
FTSE 350
4,551.10
15:45 22/11/24
n/a
n/a
FTSE All-Share
4,506.61
15:45 22/11/24
n/a
n/a
GSK
1,338.50p
15:45 22/11/24
2.21%
29.00p
Pharmaceuticals & Biotechnology
20,137.98
15:45 22/11/24
3.64%
707.65
The deal provides GSK with access to Aiolos' AIO-001, a drug ready to enter phase II clinical development for the treatment of adult patients with asthma, with potential for additional indications including chronic rhinosinusitis with nasal polyps.
GSK will pay $1bn upfront, with an extra $400m in milestone payments if targets are met.
Founded in 2023, Aiolos Bio is a San Francisco, USA and London, UK-based clinical-stage, private, biopharmaceutical company focused on treating respiratory disease.
Reporting by Frank Prenesti for Sharecast.com